Royal Bank of Canada’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-240,601
| Closed | -$31.7M | – | 7500 |
|
|
2025
Q1 | $31.7M | Buy |
240,601
+76,175
| +46% | +$9.49M | 0.01% | 1021 |
|
|
2024
Q4 | $13.7M | Buy |
164,426
+28,358
| +21% | +$2.33M | ﹤0.01% | 1596 |
|
|
2024
Q3 | $9.96M | Buy |
136,068
+95,434
| +235% | +$7.17M | ﹤0.01% | 1785 |
|
|
2024
Q2 | $2.78M | Buy |
40,634
+2,624
| +7% | +$182K | ﹤0.01% | 2654 |
|
|
2024
Q1 | $2.63M | Sell |
38,010
-29,453
| -44% | -$2.02M | ﹤0.01% | 2696 |
|
|
2023
Q4 | $4.83M | Buy |
67,463
+18,567
| +38% | +$1.07M | ﹤0.01% | 2264 |
|
|
2023
Q3 | $2.55M | Sell |
48,896
-16,320
| -25% | -$951K | ﹤0.01% | 2650 |
|
|
2023
Q2 | $4.13M | Buy |
65,216
+10,467
| +19% | +$652K | ﹤0.01% | 2242 |
|
|
2023
Q1 | $2.96M | Sell |
54,749
-997
| -2% | -$48.2K | ﹤0.01% | 2504 |
|
|
2022
Q4 | $2.95M | Buy |
55,746
+11,835
| +27% | +$593K | ﹤0.01% | 2572 |
|
|
2022
Q3 | $2.04M | Buy |
43,911
+24,967
| +132% | +$1.3M | ﹤0.01% | 2838 |
|
|
2022
Q2 | $1.08M | Sell |
18,944
-3,482
| -16% | -$197K | ﹤0.01% | 3430 |
|
|
2022
Q1 | $1.37M | Sell |
22,426
-13,996
| -38% | -$727K | ﹤0.01% | 3379 |
|
|
2021
Q4 | $1.91M | Buy |
36,422
+6,671
| +22% | +$280K | ﹤0.01% | 3198 |
|
|
2021
Q3 | $1.11M | Buy |
29,751
+10,332
| +53% | +$359K | ﹤0.01% | 3574 |
|
|
2021
Q2 | $793K | Buy |
19,419
+5,492
| +39% | +$203K | ﹤0.01% | 3859 |
|
|
2021
Q1 | $472K | Sell |
13,927
-13,503
| -49% | -$468K | ﹤0.01% | 4235 |
|
|
2020
Q4 | $872K | Sell |
27,430
-570
| -2% | -$15K | ﹤0.01% | 3615 |
|
|
2020
Q3 | $719K | Buy |
28,000
+23,109
| +472% | +$527K | ﹤0.01% | 3537 |
|
|
2020
Q2 | $125K | Sell |
4,891
-2,336
| -32% | -$47.3K | ﹤0.01% | 4715 |
|
|
2020
Q1 | $111K | Sell |
7,227
-774
| -10% | -$16.8K | ﹤0.01% | 4714 |
|
|
2019
Q4 | $275K | Sell |
8,001
-11,644
| -59% | -$140K | ﹤0.01% | 4414 |
|
|
2019
Q3 | $147K | Sell |
19,645
-1,435
| -7% | -$13.8K | ﹤0.01% | 4623 |
|
|
2019
Q2 | $274K | Sell |
21,080
-13,908
| -40% | -$178K | ﹤0.01% | 4268 |
|
|
2019
Q1 | $426K | Buy |
34,988
+4,910
| +16% | +$62.7K | ﹤0.01% | 3844 |
|
|
2018
Q4 | $343K | Sell |
30,078
-1,150
| -4% | -$18.6K | ﹤0.01% | 3983 |
|
|
2018
Q3 | $677K | Buy |
31,228
+27,168
| +669% | +$568K | ﹤0.01% | 3682 |
|
|
2018
Q2 | $72K | Buy |
4,060
+315
| +8% | +$6.4K | ﹤0.01% | 4988 |
|
|
2018
Q1 | $79K | Sell |
3,745
-1,080
| -22% | -$21K | ﹤0.01% | 4824 |
|
|
2017
Q4 | $70K | Sell |
4,825
-2,525
| -34% | -$39K | ﹤0.01% | 5017 |
|
|
2017
Q3 | $116K | Buy |
7,350
+2,725
| +59% | +$40K | ﹤0.01% | 4905 |
|
|
2017
Q2 | $57K | Sell |
4,625
-1,700
| -27% | -$19.7K | ﹤0.01% | 5052 |
|
|
2017
Q1 | $103K | Sell |
6,325
-1,184
| -16% | -$17.1K | ﹤0.01% | 4748 |
|
|
2016
Q4 | $114K | Buy |
7,509
+4,763
| +173% | +$67.3K | ﹤0.01% | 4810 |
|
|
2016
Q3 | $42K | Buy |
2,746
+62
| +2% | +$2.51K | ﹤0.01% | 5240 |
|
|
2016
Q2 | $104K | Buy |
2,684
+504
| +23% | +$18.1K | ﹤0.01% | 4769 |
|
|
2016
Q1 | $61K | Buy |
2,180
+37
| +2% | +$1.23K | ﹤0.01% | 5015 |
|
|
2015
Q4 | $115K | Buy |
2,143
+93
| +5% | +$4.69K | ﹤0.01% | 4857 |
|
|
2015
Q3 | $82K | Sell |
2,050
-2,000
| -49% | -$65.2K | ﹤0.01% | 4882 |
|
|
2015
Q2 | $129K | Buy |
4,050
+3,684
| +1,007% | +$93.4K | ﹤0.01% | 4685 |
|
|
2015
Q1 | $9K | Buy |
+366
| New | +$8.2K | ﹤0.01% | 5609 |
|
Other funds holding ITCI
KIM
HNB
Royal Bank of Canada's ITCI Position: Q2 2025 in Review
Royal Bank of Canada sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 240,601 shares — an estimated $31.7M sold.
Royal Bank of Canada first reported a position in ITCI in Q1 2015 and held it in 41 quarters. The position peaked at $31.7M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Royal Bank of Canada reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Royal Bank of Canada sold 240,601 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $31.7M.
- Royal Bank of Canada first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 41 quarters.
- Royal Bank of Canada's Intra-Cellular Therapies Inc. position peaked at $31.7M in Q1 2025.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.